

CURRICULUM VITAE

Name Sanaa Eissa Mohamed Hamed
Position Prof. of medical biochemistry and molecular biology
Department Medical biochemistry and molecular biology department
Affiliation Faculty of Medicine –Ain Shams University
Sex Female
Marital status Married and has 3 children
Citizenship Egyptian
e.mail address drsanaa_mohamed@asu.med.edu.eg
Address: Abbassia, Cairo, Egypt, 11381
Tel: 0100 178 2828
Fax:002 02 26859928

QUALIFICATIONS

1981 : M.B., B.Ch. (very good with honour), Ain Shams Faculty of Medicine.
1986 :M.Sc. (Biochemistry), Ain Shams Faculty of Medicine.
1989 :Ph.D (Biochemistry), Ain Shams Faculty of Medicine.
2009 : Diploma in medical health education profession, Suez Canal university

EMPLOYMENTS:

2000 –now : Professor of Biochemistry, Ain Shams Faculty of Medicine
2002-2009 : Supervisor of Clinical Biochemistry course, Faculty of Pharmacy,
MUST University.
2002-now : Supervisor of Clinical Molecular Biology lab, Doah Hospital.
2009-2011 : Head of Ali Khalifa Oncology Diagnostic Unit, Ain Shams Faculty of
Medicine.
2011-Now : Head of Ain Shams Faculty of Medicine Grant's Office.
2012- 2013 : Vice director of Ain Shams faculty of medicine- Quality Assurance
Unit.
2013-2016 : Visitor Professor at Armed Force college of medicine
2016-2017 : Head of Medical Biochemistry department, Ain Shams University.

ELECTED OFFICE :

- I. An external reviewer for **National Quality Assurance and Accreditation Organization for higher education (NAQAAE)**(2010-now).
- II. **The head of Promotion Committee** for Egyptian Universities Professor and Ass. Professors, Medical biochemistry branch, 2019-2022
- III. A member of Ain Shams **Ethical committee** of research , 2008-now
- IV. An executive member of the accreditation team of faculty of Medicine 2018-2013, 2008-2013
- V. A member of curricular development committee, faculty of medicine, ASU 2018-now.

- VI. An executive member of the **Quality Assurance project QUAP-2** for Ain Shams faculty of medicine, 2008-2012
- VII. The supervisor of **Internal audit team** at Ain Shams Faculty of Medicine (2008-now)
- VIII. Supervisor of Ain Shams Medical students society (2004-2009).
- IX. Head of Grant office-faculty of medicine, Ain shams university (2010-now).
- X. **Cofounder of Oncology Diagnostic Unit at Medical Biochemistry Department**, Ain Shams Faculty of Medicine in 1983,
- XI. **A member of the editorial board of the following international journals:**
 1. World journal of clinical urology
 2. International journal of molecular epidemiology and genetics
 3. Journal of Molecular Biomarkers & Diagnosis.
 4. Edorium journal of biochemistry

AWARDNESS :

- 1- **ASU Appreciation Award 2021**
جائزه الجامعه التقديرية فى العلوم الطبيه 2021
- 2- **National Excellence Prize in Advanced Technological Sciences 2011**
جائزه الدولة فى التفوق فى العلوم التكنولوجية المتقدمة 2011
- 3- **National Encouraging Prize in Medicine by the Academy of Scientific Research and Technology, 2001**
جائزه الدولة التشجيعية فى العلم الطبيه 2001
- 4- Hamburg (Germany) award for best conference presentations by the 6th Hamburg Symposium on tumor markers, 1991.
- 5- The flow cytometry award *by the* The 2nd International Conference For Lab. Techonolgy, Biochemistry, Diagnosis and Analysis, 1998.

REVIEWER:

1- For International scientific journals:

- | | |
|---|---|
| 1- Clinical cancer research | 5- British journal of urology international |
| 2- Cancer epidemiology, biomarkers prevention | 6- BMC Urology |
| 3- Clinical Biochemistry | 7- Future Oncology |
| 4- Cancer therapy journal | 8- PLOS |
| | 9- BMC Urology |
| | 10- BMC Cancer |
| | 11- BMC Medicine |

2- For research projects:

- Full bright Egyptian scholar program Master and Post-Doctrol research grant
- Newton Mosharafa PhD scholarship program interview panel
- Om Elkora, Saudi Arabia Research proposals
- STDF proposals: center of excellence, applied basic research calls
- Academy of Research and technology , Biotechnology calls
- Program of Projects, Initiatives and National Campaigns, Academy of Scientific Research and Technology, PINC-ASRT
- Middle East and North Africa – Swedish Research Partnership Programme which is funded by Swedish International Development Cooperation agency

National Program for Research & Innovation in Health and Biomedical Sciences (PRISM) (SIDA).

- Misr Elkhair organization (NGO) research proposals.

3- For promotion of international staff members

- **at Taibah University**, Madinah, Saudi Arabia
- at Sana'a University, Yaman.
- **King Abdulaziz University.**

For international thesis:

The Faculty of Postgraduate Studies and Scientific Research ,faculty of pharmacy,German university Cairo, 27th june 2010

The Faculty of Postgraduate Studies and Scientific Research ,faculty of pharmacy,German university Cairo, August 2021

RESEARCH PROJECTS:

- 1- Principal investigator of the research project** (Target based therapeutic approach towards diabetes mellitus by modifying autophagy Signaling) **funded from Health Targeted Calls from STDF, proposal no:22907, 2018-2021**
- 2- Principal investigator of the research project** (Gene editing of lncRNA-associated ceRNAs network: in treating type 2 DM). funded by JESOR from Academy of research and technology 2018-2021
- 3- Co-PI of the research project** (**MATREX (MASRI CAncer Biobank and In Tegrated Genomic solution AccREDITed Center of Scientific EXcellence)**)
Funded by STDF 2020-2022
- 4- Principle investigator of the research project ‘ screening for early molecular diagnosis of schistosomal bladder cancer’** under the program of the National

Strategy for Biotechnology and Genetic Engineering, Acadmy of Research and Technology (Phase I:1999-2004; Phase II: 2006-2009).

- 5- **A partener in FP7 project** (Multicenter Discovery of Proteomic Breast Cancer Biomarkers (CANOMICS), proposal no: 247596 , 2010-2012)
- 6- **Principal investigator of the research project** (Development of novel diagnostic test for detection of bladder cancer using nanotechnology), proposal 2013-2014 under Ain Shams Research strategic plan research proposals.
- 7- **Principal investigator of research project** (Development of novel assays for early detection of Diabetic Nephropathy) funded by Scientific Research Support &Technology Development Grant (**RSTDF**) from STDF, proposal no: 6635, 2014-2015

Scopus author ID: 7006818781 HI: 25

total citation: 1843 Total publications:98

<https://www.scopus.com/authid/detail.uri?authorId=7006818781>

ORCID:

<https://orcid.org/0000-0001-8591-3244> drsanaa_mohamed@med.asu.edu.eg

Google Scholar:

zS6isXIAAAAJ&hl

<https://scholar.google.com.eg/citations?user=zS6isXIAAAAJ&hl=en>

ASU url

<http://staff.asu.edu.eg//index.php?action=editprofile&id=sanaaeissa>

Web of Science ResearcherID is AAA-6319-2019

LIST OF PUBLICATIONS (:<https://orcid.org/0000-0001-8591-3244>)

1	Probiotic-prebiotic-synbiotic modulation of (YAP1, LATS1 and NF2 mRNAs/miR-1205/lncRNA SRD5A3-AS1) panel in NASH animal model Gadallah, S.H., Eissa, S., Ghanem, H.M., ...El Mahdy, M.M., Matboli, M. Biomedicine and Pharmacotherapy, 2021, 140, 111781
---	--

2	New insight into the role of isorhamnetin as a regulator of insulin signaling pathway in type 2 diabetes mellitus rat model: Molecular and computational approach Matboli, M., Saad, M., Hasanin, A.H., ...Bekhet, M.M., Eissa, S. Biomedicine and Pharmacotherapy, 2021, 135, 111176
3	Epigenetic modulation of autophagy genes linked to diabetic nephropathy by administration of isorhamnetin in Type 2 diabetes mellitus rats Matboli, M., Ibrahim, D., Hasanin, A.H., ...Afifi, A.M., Eissa, S. Epigenomics, 2021, 13(3), pp. 187–202
4	Toll-like receptor immune modulatory role in personalized management of colorectal cancer, review of literature Hossam, N., Matboli, M., Shehata, H.H., ...Hassan, M.K., Eissa, S. Expert Review of Precision Medicine and Drug Development, 2020, 5(6), pp. 455–468
5	<u>Determination of certain urinary microRNAs as promising biomarkers in diabetic nephropathy patients using gold nanoparticles.</u> Nossier AI, Shehata NI, Morsy SM, Saeed DF, Elsayed NM, Ismail MF, Eissa S. Anal Biochem. 2020 Nov 15;609:113967. doi: 10.1016/j.ab.2020.113967. Epub 2020 Sep 18. PMID: 32950495
6	<u>An overview on precision therapy in bladder cancer</u> A Sayed, M Munir, N Eweis, D Wael, O Shazly, AK Awad, MA Elbadawy, Eissa S Expert Review of Precision Medicine and Drug Development 5 (5), 347-361,2020
4	<u>Large-scale application of case-based learning for teaching medical biochemistry: a challenging experience with positive impacts</u> S Eissa , RM Sallam, AS Moustafa, AMA Hammouda Innovation and Education 2 (1), 1-19, 2020 DOI: 10.1186/s42862-020-0006-9
5	<u>Measurement of Urinary Level of a Specific Competing endogenous RNA network (FOS and RCAN mRNA/ miR-324-5p, miR-4738-3p, /lncRNA miR-497-HG) Enables Diagnosis of Bladder Cancer.</u> Eissa S , Safwat M, Matboli M, Zaghloul A, El-Sawalhi M, Shaheen A. Urol Oncol. 2019 Apr;37(4):292.e19-292.e27. doi: 10.1016/j.urolonc.2018.12.024. Epub 2019 Jan 14. PMID: 30654976
6	<u>Determination of certain urinary microRNAs as promising biomarkers in diabetic nephropathy patients using gold nanoparticles.</u> Nossier AI, Shehata NI, Morsy SM, Saeed DF, Elsayed NM, Ismail MF, Eissa S. Journal: Anal Biochem. 2020 Nov 15;609:113967. doi:

	10.1016/j.ab.2020.113967. Epub 2020 Sep 18. PMID: 32950495
7	<u>Measurement of Urinary Level of a Specific Competing endogenous RNA network (FOS and RCAN mRNA/ miR-324-5p, miR-4738-3p, /lncRNA miR-497-HG) Enables Diagnosis of Bladder Cancer.</u> Eissa S , Safwat M, Matboli M, Zaghloul A, El-Sawalhi M, Shaheen A. Urol Oncol. 2019 Apr;37(4):292.e19-292.e27. doi: 10.1016/j.urolonc.2018.12.024. Epub 2019 Jan 14. PMID: 30654976
8	<u>Diabetic Nephropathy Assessment: Microtubule-Associated Protein 1 Light-Chain 3B a New Promising Biomarker.</u> Mohamed MM, Eissa S , Mostafa M, Hegazy MGA. Indian J Clin Biochem. 2019 Oct;34(4):472-478. doi: 10.1007/s12291-018-0773-7. Epub 2018 Jun 22. PMID: 31686735 Free PMC article.
9	<u>Dual approach for the colorimetric determination of unamplified microRNAs by using citrate capped gold nanoparticles.</u> Nossier AI, Abdelzaher H, Matboli M, Eissa S . Mikrochim Acta. 2018 Mar 22;185(4):236. doi: 10.1007/s00604-018-2767-9. PMID: 29594755
10	<u>Caffeic Acid Modulates miR-636 Expression in Diabetic Nephropathy Rats.</u> Salem AM, Ragheb AS, Hegazy MGA, Matboli M, Eissa S . Indian J Clin Biochem. 2019 Jul;34(3):296-303. doi: 10.1007/s12291-018-0743-0. Epub 2018 Feb 26. PMID: 31391719 Free PMC article.
11	<u>Evaluation of urinary autophagy transcripts expression in diabetic kidney disease.</u> Matboli M, Azazy AEM, Adel S, Bekhet MM, Eissa S . J Diabetes Complications. 2017 Oct;31(10):1491-1498. doi: 10.1016/j.jdiacomp.2017.06.009. Epub 2017 Jun 27. PMID: 28760651
12	<u>Caffeic Acid Attenuates Diabetic Kidney Disease via Modulation of Autophagy in a High-Fat Diet/Streptozotocin- Induced Diabetic Rat.</u> Matboli M, Eissa S , Ibrahim D, Hegazy MGA, Imam SS, Habib EK. Sci Rep. 2017 May 23;7(1):2263. doi: 10.1038/s41598-017-02320-z. PMID: 28536471 Free PMC article.
13	<u>Identification and validation of a novel autophagy gene expression signature for human bladder cancer patients.</u> Eissa S , Matboli M, Awad N, Kotb Y. Tumour Biol. 2017 Apr;39(4):1010428317698360. doi: 10.1177/1010428317698360. PMID: 28381171
14	<u>Gelatin-modified gold nanoparticles for direct detection of urinary total gelatinase activity: Diagnostic value in bladder cancer.</u>

	Nossier AI, Mohammed OS, Fakhr El-Deen RR, Zaghloul AS, Eissa S. Talanta. 2016 Dec 1;161:511-519. doi: 10.1016/j.talanta.2016.09.015. Epub 2016 Sep 5. PMID: 27769440
15	<u>Urinary exosomal microRNA panel unravels novel biomarkers for diagnosis of type 2 diabetic kidney disease.</u> Eissa S, Matboli M, Aboushahba R, Bekhet MM, Soliman Y. J Diabetes Complications. 2016 Nov-Dec;30(8):1585-1592. doi: 10.1016/j.jdiacomp.2016.07.012. Epub 2016 Jul 21. PMID: 27475263
16	<u>Clinical verification of a novel urinary microRNA panel: 133b, -342 and -30 as biomarkers for diabetic nephropathy identified by bioinformatics analysis.</u> Eissa S, Matboli M, Bekhet MM. Biomed Pharmacother. 2016 Oct;83:92-99. doi: 10.1016/j.biopha.2016.06.018. Epub 2016 Jun 23. PMID: 27470555
17	<u>Prognostic and biological significance of microRNA-221 in breast cancer.</u> Eissa S, Matboli M, Sharawy A, El-Sharkawi F. Gene. 2015 Dec 10;574(1):163-7. doi: 10.1016/j.gene.2015.08.004. Epub 2015 Aug 5. PMID: 26253160
18	<u>Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis.</u> Eissa S, Matboli M, Essawy NO, Kotb YM. Tumour Biol. 2015 Dec;36(12):9545-52. doi: 10.1007/s13277-015-3722-6. Epub 2015 Jul 3. PMID: 26138586
19	<u>Urine biomarkers of schistosomiasis and its associated bladder cancer.</u> Eissa S, Matboli M, Shawky S, Essawy NO. Expert Rev Anti Infect Ther. 2015 Aug;13(8):985-93. doi: 10.1586/14787210.2015.1051032. Epub 2015 Jun 23. PMID: 26105083 Review.
20	<u>MicroRNA-10b and minichromosome maintenance complex component 5 gene as prognostic biomarkers in breast cancer.</u> Eissa S, Matboli M, Shehata HH, Essawy NO. Tumour Biol. 2015 Jun;36(6):4487-94. doi: 10.1007/s13277-015-3090-2. Epub 2015 Jan 18. PMID: 25596707
21	<u>Evaluation of urinary microRNA panel in bladder cancer diagnosis: relation to bilharziasis.</u> Eissa S, Matboli M, Hegazy MG, Kotb YM, Essawy NO. Transl Res. 2015 Jun;165(6):731-9. doi: 10.1016/j.trsl.2014.12.008. Epub

	2015 Jan 7. PMID: 25620614
22	<u>Rapid detection of urinary long non-coding RNA urothelial carcinoma associated one using a PCR-free nanoparticle-based assay.</u> Eissa S , Matboli M, Essawy NO, Shehta M, Kotb YM. Biomarkers. 2015;20(3):212-7. doi: 10.3109/1354750X.2015.1062918. Epub 2015 Jul 13. PMID: 26161701
23	<u>Evaluation of urinary miRNA-96 as a potential biomarker for bladder cancer diagnosis.</u> Eissa S , Habib H, Ali E, Kotb Y. Med Oncol. 2015 Jan;32(1):413. doi: 10.1007/s12032-014-0413-x. Epub 2014 Dec 16. PMID: 25511320 Clinical Trial.
24	<u>Breast tissue-based microRNA panel highlights microRNA-23a and selected target genes as putative biomarkers for breast cancer.</u> Eissa S , Matboli M, Shehata HH. Transl Res. 2015 Mar;165(3):417-27. doi: 10.1016/j.trsl.2014.10.001. Epub 2014 Oct 31. PMID: 25445205
25	<u>The prognostic value of histidine-rich glycoprotein RNA in breast tissue using unmodified gold nanoparticles assay.</u> Eissa S , Azzazy HM, Matboli M, Shawky SM, Said H, Anous FA. Appl Biochem Biotechnol. 2014 Sep;174(2):751-61. doi: 10.1007/s12010-014-1085-x. PMID: 25091325
26	<u>Evaluation of histidine-rich glycoprotein tissue RNA and serum protein as novel markers for breast cancer.</u> Matboli M, Eissa S , Said H. Med Oncol. 2014 Apr;31(4):897. doi: 10.1007/s12032-014-0897-4. Epub 2014 Feb 25. PMID: 24567057
27	<u>Evaluation of urinary HURP mRNA as a marker for detection of bladder cancer: relation to bilharziasis.</u> Eissa S , Matboli M, Mansour A, Mohamed S, Awad N, Kotb YM. Med Oncol. 2014 Feb;31(2):804. doi: 10.1007/s12032-013-0804-4. Epub 2013 Dec 28. PMID: 24375315
28	<u>Direct detection of hyaluronidase in urine using cationic gold nanoparticles: a potential diagnostic test for bladder cancer.</u> Nossier AI, Eissa S , Ismail MF, Hamdy MA, Azzazy HM. Biosens Bioelectron. 2014 Apr 15;54:7-14. doi: 10.1016/j.bios.2013.10.024. Epub 2013 Oct 31.

	PMID: 24240162
29	<p><u>Direct detection of unamplified hepatoma upregulated protein RNA in urine using gold nanoparticles for bladder cancer diagnosis.</u></p> <p>Eissa S, Shawky SM, Matboli M, Mohamed S, Azzazy HM. Clin Biochem. 2014 Jan;47(1-2):104-10. doi: 10.1016/j.clinbiochem.2013.10.022. Epub 2013 Oct 29. PMID: 24183881</p>
30	<p><u>The diagnostic efficacy of urinary survivin and hyaluronidase mRNA as urine markers in patients with bladder cancer.</u></p> <p>Eissa S, Badr S, Barakat M, Zaghloul AS, Mohanad M. Clin Lab. 2013;59(7-8):893-900. doi: 10.7754/clin.lab.2012.120623. PMID: 24133921</p>
31	<p><u>Evaluation of urinary human telomerase reverse transcriptase mRNA and scatter factor protein as urine markers for diagnosis of bladder cancer.</u></p> <p>Eissa S, Motawi T, Badr S, Zaghloul A, Maher A. Clin Lab. 2013;59(3-4):317-23. doi: 10.7754/clin.lab.2012.120507. PMID: 23724620</p>
32	<p><u>The value of combined use of survivin mRNA and matrix metalloproteinase 2 and 9 for bladder cancer detection in voided urine.</u></p> <p>Eissa S, Badr S, Elhamid SA, Helmy AS, Nour M, Esmat M. Dis Markers. 2013;34(1):57-62. doi: 10.3233/DMA-2012-0923. PMID: 22960341 Free PMC article.</p>
33	<p><u>Detection of hyaluronidase RNA and activity in urine of schistosomal and non-schistosomal bladder cancer.</u></p> <p>Eissa S, Shehata H, Mansour A, Esmat M, El-Ahmady O. Med Oncol. 2012 Dec;29(5):3345-51. doi: 10.1007/s12032-012-0295-8. Epub 2012 Jul 4. PMID: 22760792</p>
34	<p><u>Urinary retinoic acid receptor-β2 gene promoter methylation and hyaluronidase activity as noninvasive tests for diagnosis of bladder cancer.</u></p> <p>Eissa S, Zohny SF, Shehata HH, Hegazy MG, Salem AM, Esmat M. Clin Biochem. 2012 Apr;45(6):402-7. doi: 10.1016/j.clinbiochem.2012.01.010. Epub 2012 Jan 18. PMID: 22286019</p>
35	<p><u>Aberrant methylation of RARbeta2 and APC genes in voided urine as molecular markers for early detection of bilharzial and nonbilharzial bladder cancer.</u></p> <p>Eissa S, Swellam M, El-Khouly IM, Kassim SK, Shehata H, Mansour A, Esmat M, Nossier AI, Hamdy MA, Awad NM, El-Ahmady O. Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1657-64. doi: 10.1158/1055-9965.EPI-11-0237. Epub 2011 Jun 15. PMID: 21680534</p>
36	<p><u>The clinical relevance of urine-based markers for diagnosis of bladder cancer.</u></p> <p>Eissa S, Swellam M, Amin A, Balbaa ME, Yacout GA, El-Zayat TM. Med Oncol. 2011 Jun;28(2):513-8. doi: 10.1007/s12032-010-9422-6. Epub</p>

	2011 Mar 25. PMID: 21437743
37	<u>Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase-2 in patients with bladder cancer.</u> Eissa S , Shabayek MI, Ismail MF, El-Allawy RM, Hamdy MA. IUBMB Life. 2010 May;62(5):394-9. doi: 10.1002/iub.325. PMID: 20408180
38	<u>Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer.</u> Eissa S , Zohny SF, Swellam M, Mahmoud MH, El-Zayat TM, Salem AM. Clin Biochem. 2008 Nov;41(16-17):1335-41. doi: 10.1016/j.clinbiochem.2008.08.085. Epub 2008 Sep 9. PMID: 18804101
39	<u>A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot.</u> Eissa S , Swellam M, Labib RA, El-Zayat T, El Ahmady O. J Urol. 2009 Mar;181(3):1353-60. doi: 10.1016/j.juro.2008.10.102. Epub 2009 Jan 29. PMID: 19185322
40	<u>Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.</u> Eissa S , Zohny SF, Zekri AR, El-Zayat TM, Maher AM. Med Oncol. 2010 Dec;27(4):1286-94. doi: 10.1007/s12032-009-9375-9. Epub 2009 Dec 11. PMID: 20012564
41	<u>Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer.</u> Eissa S , Swellam M, Shehata H, El-Khouly IM, El-Zayat T, El-Ahmady O. J Urol. 2010 Feb;183(2):493-8. doi: 10.1016/j.juro.2009.10.024. Epub 2009 Dec 14. PMID: 20006858
42	<u>The diagnostic efficacy of urinary TGF-beta1 and VEGF in bladder cancer: comparison with voided urine cytology.</u> Eissa S , Salem AM, Zohny SF, Hegazy MG. Cancer Biomark. 2007;3(6):275-85. doi: 10.3233/cbm-2007-3601. PMID: 18048965
43	<u>Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.</u> Eissa S , Ali-Labib R, Swellam M, Bassiony M, Tash F, El-Zayat TM. Eur Urol. 2007 Nov;52(5):1388-96. doi: 10.1016/j.eururo.2007.04.006. Epub 2007 Apr 10.

	PMID: 17466450
44	<p><u>Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer.</u></p> <p>Eissa S, Swellam M, Ali-Labib R, Mansour A, El-Malt O, Tash FM. J Urol. 2007 Sep;178(3 Pt 1):1068-72. doi: 10.1016/j.juro.2007.05.006. Epub 2007 Jul 20. PMID: 17644139</p>
45	<p><u>Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.</u></p> <p>Hutterer GC, Karakiewicz PI, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Serretta V, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Perrotte P, Lotan Y, Marberger MJ, Shariat SF. BJU Int. 2008 Mar;101(5):561-5. doi: 10.1111/j.1464-410X.2007.07352.x. PMID: 18257856</p>
46	<p><u>Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.</u></p> <p>Shariat SF, Marberger MJ, Lotan Y, Sanchez-Carbayo M, Zippe C, Lüdecke G, Boman H, Sawczuk I, Friedrich MG, Casella R, Mian C, Eissa S, Akaza H, Serretta V, Huland H, Hedelin H, Raina R, Miyanaga N, Sagalowsky AI, Roehrborn CG, Karakiewicz PI. J Urol. 2006 Sep;176(3):919-26; discussion 926. doi: 10.1016/j.juro.2006.04.017. PMID: 16890655</p>
47	<p><u>Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder.</u></p> <p>Karakiewicz PI, Benayoun S, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Marberger MJ, Shariat SF. BJU Int. 2006 May;97(5):997-1001. doi: 10.1111/j.1464-410X.2006.06036.x. Epub 2006 Mar 17. PMID: 16542342</p>
48	<p><u>Real-time PCR hTERT mRNA pattern in tumor core, edge, resection margin, and lymph nodes in laryngeal tumors: relation to proliferative index and impact on prognosis.</u></p> <p>Eissa S, Kenawy G, Moteleb FA, El-Makhzangy AN, Nassar M. Clin Biochem. 2005 Oct;38(10):873-8. doi: 10.1016/j.clinbiochem.2005.06.008. PMID: 16095587</p>
49	<p><u>Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.</u></p> <p>Shariat SF, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R,</p>

	Mian C, Friedrich MG, Eissa S, Akaza H, Sawczuk I, Serretta V, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Wians F Jr, Roehrborn CG, Lotan Y, Perrotte P, Benayoun S, Marberger MJ, Karakiewicz PI. J Urol. 2005 May;173(5):1518-25. doi: 10.1097/01.ju.0000154696.48217.75. PMID: 15821471
50	<u>Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs.</u> Eissa S, Kassim SK, Labib RA, El-Khouly IM, Ghaffer TM, Sadek M, Razek OA, El-Ahmady O. Cancer. 2005 Apr 1;103(7):1356-62. doi: 10.1002/cncr.20902. PMID: 15717321
51	<u>HER2/neu expression in bladder cancer: relationship to cell cycle kinetics.</u> Eissa S, Ali HS, Al Tonsi AH, Zagloul A, El Ahmady O. Clin Biochem. 2005 Feb;38(2):142-8. doi: 10.1016/j.clinbiochem.2004.09.004. PMID: 15642276
52	<u>Cell cycle regulators in bladder cancer: relationship to schistosomiasis.</u> Eissa S, Ahmed MI, Said H, Zaghloul A, El-Ahmady O. IUBMB Life. 2004 Sep;56(9):557-64. doi: 10.1080/15216540400013903. PMID: 15590562
53	<u>Comparison of cytokeratin 20 RNA and angiogenin in voided urine samples as diagnostic tools for bladder carcinoma.</u> Eissa S, Kenawy G, Swellam M, El-Fadle AA, Abd El-Aal AA, El-Ahmady O. Clin Biochem. 2004 Sep;37(9):803-10. doi: 10.1016/j.clinbiochem.2004.05.027. PMID: 15329320
54	<u>Emerging role of p53, bcl-2 and telomerase activity in Egyptian breast cancer patients.</u> Swellam M, Ismail M, Eissa S, Hamdy M, Mokhtar N. IUBMB Life. 2004 Aug;56(8):483-90. doi: 10.1080/15216540400010834. PMID: 15545228
55	<u>Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer.</u> Eissa S, Labib RA, Mourad MS, Kamel K, El-Ahmady O. Eur Urol. 2003 Dec;44(6):687-94. doi: 10.1016/s0302-2838(03)00417-2. PMID: 14644121
56	<u>Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers.</u> Eissa S, Kassim S, El-Ahmady O. Curr Opin Obstet Gynecol. 2003 Oct;15(5):395-403. doi: 10.1097/00001703-200310000-00008.

	PMID: 14501243 Review.
57	<p><u>Diagnostic value of urinary molecular markers in bladder cancer.</u> Eissa S, Swellam M, el-Mosallamy H, Mourad MS, Hamdy N, Kamel K, Zaglol AS, Khafagy MM, el-Ahmady O. <i>Anticancer Res.</i> 2003 Sep-Oct;23(5b):4347-55. PMID: 14666650</p>
58	<p><u>Tumor suppressor protein p53 and anti-p53 autoantibodies in pediatric rheumatological diseases.</u> El-Sayed ZA, Farag DH, Eissa S. <i>Pediatr Allergy Immunol.</i> 2003 Jun;14(3):229-33. doi: 10.1034/j.1399-3038.2003.00033.x. PMID: 12787304</p>
59	<p><u>Diagnostic Value of Urinary Molecular</u> S EISSA, M SWELLAM, H EL-MOSALLAMY, MS MOURAD, N HAMDY, ... <i>Anticancer research</i> 23, 4347-4356, 2003</p>
60	<p><u>Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers</u> S Eissa, S Kassim, O El-Ahmady <i>Current Opinion in Obstetrics and Gynecology</i> 15 (5), 395-403, 2003</p>
61	<p>The expression of Bcl-2 and TGF-α in some dermatoses S Eissa, R Labib, A Moustafa, M Ismail, S Nassar, A Zidan, ... <i>Journal of the European Academy of Dermatology & Venereology</i> 16, 198-2002</p>
62	<p><u>Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.</u> Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A. <i>J Urol.</i> 2002 Aug;168(2):465-9. PMID: 1213128</p>
63	<p>Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up. O El-Ahmady, E El-Salaby, M Mahmoud, MA Wahab, S Eissa, A Khalifa <i>Anticancer research</i> 22 (4), 2493-2499 342002</p>
64	<p>Deletion of p16 and p15 genes In schistosomiasis-associated bladder cancer (SABC) S Eissa, R Ali-Labib, A Khalifa <i>Clinica chimica acta</i> 300 (1-2), 159-169,2000</p>
65	<p><u>EXPRESSION OF p21WAF1/CIP1 IN BLADDER CANCER: RELATION TO SCHISTOSOMIASIS</u> A Khalifa, S Eissa, M Swelam, Y Shaker, MA Fattah <i>Biochemical Society Transactions</i> 28 (5), A368-A368,2000</p>
66	Expression of epidermal growth factor and epidermal growth factor receptor

	in bladder cancer O El-Ahmady, Z El-Dardery, AG El-Din, MA Shafie, S Eissa, A Khalifa BIOCHEMICAL SOCIETY TRANSACTIONS 28 (5), A218-A218, 2000
67	Determination of cytosolic citrulline and nitrate as indicators of nitric oxide in bladder cancer: possible association with basic fibroblast growth factor A Khalifa, S Eissa, A Aziz Clinical Biochemistry 32 (8), 635-638, 1999
68	Correlation between EBV DNA and Rearrangement and Expression of Bcl-2 Gene in Aggressive Non-Hodgkin's Lymphoma S Eissa, SK Kassim, M Imam, A Khalifa IUBMB life 48 (2), 231-236, 1999
69	Expression of p21 WAF1/CIP1 in Bladder Cancer: Relation to Schistosomiasis S Eissa, M Swelam, Y Shaker, MA Fattah, A Khalifa IUBMB life 48 (1), 115-119, 1999
70	Regulators of apoptosis in human breast cancer S Eissa, R Labib, A Khalifa, N Swelam, F Khalil, AM El-Shenawy Clinical biochemistry 32 (5), 321-326, 1999
71	Quantitation of bcl-2 protein in bladder cancer tissue by enzyme immunoassay: comparison with Western blot and immunohistochemistry S Eissa, LS Seada Clinical Chemistry 44 (7), 1423-1429, 1998
72	Comparison of flow cytometric DNA content analysis in fresh and paraffin-embedded ovarian neoplasms: a prospective study S Eissa, A Khalifa, M Laban, A Elian, WE Bolton British journal of cancer 77 (3), 421-425, 1998
73	Epstein-Barr virus, human papillomavirus, and flow cytometric cell cycle kinetics in nasopharyngeal carcinoma and inverted papilloma among Egyptian patients SK Kassim, SA Ibrahim, S Eissa, SSA Zaki, MA El-Begermy, MH Abdou, ... Disease markers 14 (2), 113-120, 1998
74	Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer. S Eissa, A Khalifa, A El-Gharib, N Salah, MK Mohamed Anticancer research 17 (4B), 3091-3097, 1997
75	The value of serum CA-15.3, DNA ploidy and cell cycle kinetics in breast tumors. T Bahig, S Eissa, L Emad CLINICAL CHEMISTRY 43, 555-555, 1997
76	Flow cytometric cell cycle kinetics and quantitative measurement of c-erbB-2 and mutant p53 proteins in normal, hyperplastic, and malignant endometrial biopsies

	S Eissa , MA Saada, T El-Sharkawy Clinical biochemistry 30 (3), 209-214, 1997
77	Altered endometrial progesterone/oestrogen receptor ratio in luteal phase defect. KH Abd-el-Maeboud, S Eissa, AS Kamel Disease markers 13 (2), 107
78	DNA ploidy in hepatic cirrhosis, dysplasia and carcinoma S Eissa, M Wahed, A Ismail, K Amer, A Khalifa, A ElNaggar Oncology Reports 4 (2), 443-445,1997
79	Quantitative immunological detection of total estrogen receptor (cytosolic and nuclear) in term decidua of preeclampsia: a preliminary study S Eissa, MM Mostafa, AAEA El-Gendy, IA Senna Clinical chemistry 43 (2), 405-407,1997
80	CA19-9 and DNA ploidy in bladder cancer patients A Khalifa, MM AbdelFattah, S Eissa , MK Mohamed, SAK ElDin CLINICAL CHEMISTRY 42 (6), 688-688, 1996
81	P53 mutations in egyptian bladder-cancer M WEINTRAUB, HM KHALED, AR ZEKRI, A BAHNASI, S Eissa , ... International journal of oncology 7 (6), 1269-1274, 1995
82	Multivariate analysis of DNA ploidy, steroid hormone receptors, and CA 125 as prognostic factors in ovarian carcinoma: a prospective study. S Eissa , A Khalifa, M Laban, MK Mohamed, A Elian Nutrition (Burbank, Los Angeles County, Calif.) 11 (5 Suppl), 622-626, 1995
83	THE VALUE OF THE LYSOSOMAL PROTEASE CATHEPSIN-D IN EGYPTIAN BLADDER-CANCER S EISSA , O Elahmady, AG ELDIN, T HELAL, I Khalaf Oncology reports 1 (4), 849-852,1994
84	TPS IN SERUM AND URINE OF EGYPTIAN BLADDER-CANCER PATIENTS O Elahmady, S Eissa , AG ELDIN, A Vandalen, RD VANCAUBERGH Oncology reports 1 (3), 519-521,1994
85	Luminoimmunometric assay of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA-125) in breast cancer patients O El-Ahmady, H A-B, S Eissa Disease markers 11,1993
86	Expression of CA 125 in breast cancer. S Eissa , A Khalifa, A AbouGhalia, H Abdalla, A Abou Ghalia In: R Klapdor (ed.), tumor associated antigens, Oncogenes, receptors ...,1992
87	The Predictive Value of Epidermal Growth Factor Receptor (EGFR) in Egyptian Breast Cancer: Correlation with Steroid Receptors (ER & PgR) S Eissa , A Khalifa, E El-Salahi, E Madi

	JOURNAL OF TUMOR MARKER ONCOLOGY 7 (4), 25-25,1992
88	<u>Tumor Markers in Malignant and Benign breast Tissue: CA15. 3, CEA and Ferritin in Cytosol and Membrane-Enriched Fraction</u> S Eissa, A Khalifa, O El-Ahmady JOURNAL OF TUMOR MARKER ONCOLOGY 7 (2), 43-43,1992
89	<u>Determination of Estrogen Receptor (ER) in Malignant and Benign Breast Tissue Using Monoclonal Antibody (MAB)</u> S Eissa, A Khalifa, O El-Ahmady JOURNAL OF TUMOR MARKER ONCOLOGY 7 (2), 53-53, 1992
90	<u>Predictive value of tumor markers in endometrial hyperplasia and adenocarcinoma</u> O EL-AHMADY, E SAKR, O KHANDIL, A KHALIFA, S EISSL Journal of tumor marker oncology 4 (1), 71-75, 1989
91	<u>Certain tumor markers in Bilharzial patients in relation to bladder cancer</u> O EL AHMADY, A Khalifa, S Eissa, MT Ibrahim Journal of tumor marker oncology 3 (2), 227-236,

Books:

1. **Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)^{†AUTOPHAGY}**
<https://doi.org/10.1080/15548627.2020.1797280>
Taylor and Francis publisher
175 pages in press
1. **Apoptosis Inhibitory Gene in Bladder Cancer Diagnosis: Molecular Screening for Bladder Cancer** Project PI: Sanaa Eissa Ain Shams Faculty of Medicine
Sanaa Eissa, Marrwa Matboli, Randa Ali-Labib
edited by Sanaa Eissa, 02/2012; LAP Lambert Academic Publishing AG & Co KG.,
ISBN: 9783846586266
2. **Protein Phosphorylation and Dephosphorylation**
A mechanism of acute and reversible regulation of protein function
Sanaa Eissa and Omar El-Ahmady
edited by Sanaa Eissa, 03/2012; LAP Lambert Academic Publishing AG & Co KG.,
ISBN: 978-3-8484-2840-3
3. Detection of methylated RAR in urine of bladder cancer patients: Molecular Screening for Bladder Cancer Project PI: Sanaa Eissa Ain Shams Faculty of Medicine
Ahmed Ibrahim and Sanaa Eissa
edited by Sanaa Eissa, 03/2012; LAP Lambert Academic Publishing AG & Co KG.,
ISBN: **978-3-8473-7924-9**
4. Methylation of APC tumor suppressor gene In bladder cancer : Molecular Screening for Bladder Cancer Project PI: Prof Sanaa Eissa, Medical Biochemistry & Molecular biology department
Lilian Ramzy , Sanaa Eissa, samar kassim
edited by Sanaa Eissa, 03/2012; LAP Lambert Academic Publishing AG & Co KG.,
ISBN: **978-3-8484-1376-8**